版本:
中国

BRIEF-Santhera expects CHMP opinion about Raxone in Q3 2017

May 19 SANTHERA PHARMACEUTICALS HOLDING AG

* PROVIDES UPDATE ON TIMELINE FOR APPLICATION OF RAXONE® IN DUCHENNE MUSCULAR DYSTROPHY IN EUROPE

* WE ARE NOW EXPECTING TO RECEIVE A REQUEST FOR SUPPLEMENTARY INFORMATION TO FURTHER SUPPORT CLINICAL RELEVANCE OF OUR DATA

* WE ARE WORKING CLOSELY WITH CHMP TO CONCLUDE APPLICATION PROCESS AND ANTICIPATE AN OPINION IN Q3 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐